Market capitalization | $773.76m |
Enterprise Value | $818.21m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 105.99 |
P/S ratio (TTM) P/S ratio | 100.23 |
P/B ratio (TTM) P/B ratio | 1.35 |
Sales growth (TTM) Sales growth | -24.47% |
Turnover (TTM) Turnover | $7.72m |
As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.
4 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:
4 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:
Dec '23 |
+/-
%
|
||
Turnover | 7.72 7.72 |
2%
2%
|
|
Gross income | -19 -19 |
7%
7%
|
|
EBITDA | - - |
-
|
EBIT (operating result) EBIT | -73 -73 |
3%
3%
|
Net profit | -82 -82 |
3%
3%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
Head office | Australia |
CEO | Silviu Itescu |
Employees | 83 |
Founded | 2004 |
Website | www.mesoblast.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.